New drug combo could simplify breast cancer treatment for younger women
NCT ID NCT07159451
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether the drug elacestrant alone works as well as elacestrant combined with a drug that suppresses ovarian function (leuprorelin) in premenopausal women with early-stage, hormone-receptor-positive breast cancer. The study involves 140 women who will take the medication for 4 weeks before their scheduled breast surgery. Researchers will measure changes in a tumor growth marker (Ki67) to see how well the drugs are working.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
elacestrant (a hormone-blocking drug) and leuprorelin (a drug that temporarily stops ovarian function)
What this could lead to
If successful, this could show that elacestrant alone is as effective as combining it with ovarian suppression, potentially offering a simpler treatment option for premenopausal women with early-stage breast cancer.
What could go wrong
This is a small, early-phase study with only 140 participants, and it measures a biomarker (Ki67) rather than long-term outcomes like survival. The results may not translate to better cancer control or cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Gustave Roussy
RECRUITINGVillejuif, France
Contact Phone: •••-•••-•••• Email: •••••@•••••